Classes
DEA Class; Rx
Common Brand Names; Forteo, parathyroid hormone, Bonsity
- Parathyroid Hormone Analogs
Description
Recombinant human parathyroid hormone
Used for the treatment of osteoporosis in patients with high risk of fracture
Boxed warning regarding the risk of osteosarcoma; not recommended for use in patients at risk for osteosarcoma
Indications
Treatment of postmenopausal women with osteoporosis at high risk for fracture who have failed or are intolerant to other available osteoporosis therapy; reduces risk of vertebral and nonvertebral fractures
Increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture, or have failed or are intolerant to other available therapy
Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (prednisone ≥5 mg/day) at high risk for fracture, or have failed or are intolerant to other available therapy
Contraindications
Hypersensitivity
Adverse Effects
- Pain (21.3%)
- Arthralgia (10.1%)
- Rhinitis (9.6%)
- Asthenia (8.7%)
- Nausea (8.5%)
- Dizziness (8%)
- Headache (7.5%)
- Hypertension (7.1%)
- Increased cough (6.4%)
- Pharyngitis (5.5%)
- Constipation (5.4%)
- Dyspepsia (5.2%)
- Diarrhea (5.1%)
- Rash (4.9%)
- Insomnia (4.3%)
- Depression (4.1%)
- Pneumonia (3.9%)
- Vertigo (3.8%)
- Dyspnea (3.6%)
- Neck pain (3%)
- Vomiting (3%)
- Syncope (2.6%)
- Leg cramps (2.6%)
- Angina pectoris (2.5%)
- Gastrointestinal disorder (2.3%)
- Tooth disorder (2%)
Warnings
Transient orthostatic hypotension may occur with initial doses
May exacerbate urolithiasis; consider risk/benefit in patients with active or recent urolithiasis
Pregnancy and Lactation
There are no available data on use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; consider discontinuing drug when pregnancy is recognized
Not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on breastfed infant; because of potential for osteosarcoma shown in animal studies, advise patients that breastfeeding is not recommended during therapy
Maximum Dosage
20 mcg/day subcutaneously for osteoporosis.
20 mcg/day subcutaneously for osteoporosis.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Teriparatide rDNA origin
prefilled injectable pen
- 250mcg/mL (2.4 mL [Forteo, Bonsity])
